Humanwell Healthcare (Group) Co. Ltd. has disclosed compounds acting as phosphodiesterase PDE4 inhibitors, particularly PDE4B, reported to be useful for the treatment of respiratory, gastrointestinal, inflammatory, dermatological, ophthalmic and neurological disorders, transplant rejection and cancer.